Kenneth Pienta buys 2,720 shares of Cue Biopharma, Inc for $40,980
|
COMPANY INFORMATION
|
||
|
CUE by TradingView
|
Company Info:
Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body to transform the treatment of cancer and autoimmune diseases. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells), is designed to harness the body’s intrinsic immune system without the need for ex vivo manipulation.
|
LATEST INSIDER ACTIVITY
|
||
|
INSIDER:
Kenneth Pienta
SHARES BOUGHT:
$40,980
PURCHASE DATE:
1/20/2021 |
TITLE:
Chief Medical Director
% INCREASE:
136%
FILE DATE:
1/22/2021
|
|
|
INSIDER PURCHASE PRICE
N/A
|
||
Insider Notes:
Fletcher Aaron G.L. purchase of $82,776 on 11/24/2020
Gray Cameron purchase of $151,500 on 9/29/2020
Gray Cameron purchase of $151,500 on 9/29/2020
|
ANALYST RECOMMENDATION
|
||
|
TARGET PRICE:
$31.17 TARGET GAIN:
70% |
AVERAGE RATING:
BUY ANALYST COVERING:
6 |
|
| IMPORTANT DISCLOSURE | ||
|
TECHNICAL ANALYSIS
|
||
|
|
|
|